Hospital readmission and first-time admitted patients with schizophrenia: Smoking patients had higher hospital readmission rate than non-smoking patients

International Journal of Psychiatry in Medicine

Volumn 40, Issue 3, 2010, Pages 247-257

  Kobayashi, Mika ^a   Ito, Hiroto ^a   Okumura, Yasuyuki ^a   Mayahara, Ken ^b   Matsumoto, Yoshio ^b   Hirakawa, Junichi ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b Japanese Association of Psychiatric Hospitals   (Japan)

Author keywords

hospital readmission; schizophrenia; smoking

Indexed keywords

ADULT; ARTICLE; CIGARETTE SMOKING; DISEASE COURSE; FEMALE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SOCIAL INTERACTION;

ADULT; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PATIENT READMISSION; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SMOKING; STATISTICS AS TOPIC; SURVIVAL RATE; YOUNG ADULT;

EID: 78049499316     PISSN: 00912174     EISSN: 15413527     Source Type: Journal    
DOI: 10.2190/PM.40.3.b     Document Type: Article

References (32)

1. Denscombe M. UK health policy and "underage" smokers: The case for smoking cessation services. Health Policy 2007;80:69-76.
2. U.S. Government Publishing Service. The health benefits of smoking cessation (DHHD Publication No. (CDC) 90-8416). Maryland.
3. Ministry of Health, Labor, and Welfare: National Health and Nutrition Survey in Japan, 2006 (in Japanese). 2006.
4. McCloughen A. The association between schizophrenia and cigarette smoking: A review of the literature and implications for mental health nursing practice. International Journal of Mental Health Nursing 2003;12:119-129.
5. El-Guebaly N, Cathcart J, Currie S, Brown D, Gloster S. Public health and therapeutic aspects of smoking bans in mental health and addiction settings. Psychiatric Service 2002;53:1617-1622.
6. Lasser K, Boyd J, Woolhandler S, Himmelstein D, McCormick D, Bor D. Smoking and mental illness: A population-based prevalence study. Journal of the American Medical Association 2000;284:2606-2610.
7. George, T. P. V. J. Nicotine addiction in psychiatric disorders. Psychiatric Times 2001; 18:39-42.
8. McChargue D, Gulliver S, Hitsman B. Would smokers with schizophrenia benefit from a more flexible approach to smoking treatment? Addiction 2002;97:785-793; discussion 795-800.
9. Eastwood R. Weeding out. Lancet 1993;341:1316.
10. Kelly C, McCreadie R. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. American Journal of Psychiatry 1999;156:1751-1757.
11. Monnelly E. Instability before discharge and previous psychiatric admissions as predictors of early readmission. Psychiatric Service 1997;48:1584-1586.
12. Bezchlibnyk-Butler, K. J. J. J. Clinical handbook of psychotropic drugs (8th ed.). Hogrefe & Huber, Seattle, WA, 1998.
13. Inagaki A IT, Fujii Y, et al. Equivalent dose of psychotropics. Seiwa Shoten, Tokyo, 1999 (in Japanese).
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (3rd ed, rev.). Washington, DC, 1987.
15. Piersma H, Boes J. The GAF and psychiatric outcome: A descriptive report. Community Mental Health Journal 1997;33:35-41.
16. Moos R, Nichol A, Moos B. Global assessment of functioning ratings and the allocation and outcomes of mental health services. Psychiatric Service 2002;53: 730-737.
17. Kline R. Beyond significance testing: Reforming data analysis methods in behavioral research. American Psychological Association, Washington, DC, 2004.
18. Hosmer, D. W. L. S. Applied survival analysis: Regression modeling of time to event data (2nd ed). Wiley-Interscience, New Jersey, 2008.
19. R Development Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, 2008.
20. Goff D, Henderson D, Amico E. Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. American Journal of Psychiatry 1992;149:1189-1194.
21. Akvardar Y, Demiral Y, Ergor G, Ergor A. Substance use among medical students and physicians in a medical school in Turkey. Social Psychiatry and Psychiatric Epidemiology 2004;39:502-506.
22. Batel P. Addiction and schizophrenia. European Psychiatry 2000;15:115-122.
23. Weisman R. Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: A case report. International Journal of Psychiatry in Medicine 2003;33:85-89.
24. de Leon J, Dadvand M, Canuso C, White A, Stanilla J, Simpson G. Schizophrenia and smoking: An epidemiological survey in a state hospital. American Journal of Psychiatry 1995;152:453-455.
25. Tang Y, Gillespie C, Epstein M, Mao P, Jiang F, Chen Q, Cai Z, Mitchell P. Gender differences in 542 Chinese inpatients with schizophrenia. Schizophrenia Research 2007;97:88-96.
26. Tang Y, George T, Mao P, Cai Z, Chen Q. Cigarette smoking in Chinese male inpatients with schizophrenia: A cross-sectional analysis. Journal of Psychiatric Research 2007;41:43-48.
27. Aguilar M, Gurpegui M, Diaz F, de Leon J. Nicotine dependence and symptoms in schizophrenia: Naturalistic study of complex interactions. British Journal of Psychiatry 2005;186:215-221.
28. Evins A, Cather C, Culhane M, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, Henderson D, Schoenfeld D, Rigotti N, Goff D. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. Journal of Clinical Psychopharmacology 2007;27:380-386.
29. de Leon J, Diaz F, Aguilar M, Jurado D, Gurpegui M. Does smoking reduce akathisia? Testing a narrow version of the self-medication hypothesis. Schizophrenic Research 2006;86:256-268.
30. Olincy A, Harris J, Johnson L, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe G, Leonard S, Stevens K, Stevens J, Martin L, Adler L, Soti F, Kem W, Freedman R. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Archives of General Psychiatry 2006;63:630-638.
31. Freedman R, Olincy A, Buchanan R, Harris J, Gold J, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball M, Kutnick J, Pender V, Martin L, Stevens K, Wagner B, Zerbe G, Soti F, Kem W. Initial phase 2 trial of a nicotinic agonist in schizophrenia. American Journal of Psychiatry 2008;165:1040-1047.
32. Green M, Hawranik P. Smoke-free policies in the psychiatric population on the ward and beyond: A discussion paper. International Journal of Nursing Studies 2008;45:1543-1549.